Nucryst Pharmaceuticals has shaken up its management and shelved one of its development programs. Nucryst announced that it had "discontinued the development of, and out-licensing initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease."

David C. McDowell, vice president operations, adds R&D responsibilities to his job description and Edward Gaj has been named vice president marketing. Katherine J. Turner, PhD, vice president research and development, is leaving to explore outside opportunities.

- read Nucryst's release [1]